Sangamo Therapeutics Announces Alignment With FDA On Accelerated Approval Pathway For ST-920 In Fabry Disease, BLA Submission Expected In 2025
Portfolio Pulse from Benzinga Newsdesk
Sangamo Therapeutics has reached an agreement with the FDA on an accelerated approval pathway for its ST-920 treatment for Fabry disease. The company plans to submit a Biologics License Application (BLA) in 2025.
October 22, 2024 | 12:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sangamo Therapeutics has secured an accelerated approval pathway with the FDA for its ST-920 treatment for Fabry disease, with a BLA submission planned for 2025.
The agreement with the FDA on an accelerated approval pathway is a positive development for Sangamo Therapeutics, as it could lead to faster market entry for ST-920, potentially boosting future revenues. The planned BLA submission in 2025 indicates a clear regulatory path forward.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100